[go: up one dir, main page]

BR0115989A - Preparação farmacêutica na forma de uma suspensão compreendendo um ingrediente ativo instável a ácido - Google Patents

Preparação farmacêutica na forma de uma suspensão compreendendo um ingrediente ativo instável a ácido

Info

Publication number
BR0115989A
BR0115989A BR0115989-5A BR0115989A BR0115989A BR 0115989 A BR0115989 A BR 0115989A BR 0115989 A BR0115989 A BR 0115989A BR 0115989 A BR0115989 A BR 0115989A
Authority
BR
Brazil
Prior art keywords
suspension
acid
active ingredient
pharmaceutical preparation
labile active
Prior art date
Application number
BR0115989-5A
Other languages
English (en)
Inventor
Rango Dietrich
Rudolf Linder
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of BR0115989A publication Critical patent/BR0115989A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"PREPARAçãO FARMACêUTICA NA FORMA DE UMA SUSPENSãO COMPREENDENDO UM INGREDIENTE ATIVO INSTáVEL A áCIDO". A presente invenção refere-se ao campo da tecnologia farmacêutica e descreve uma nova preparação farmacêutica na forma de uma suspensão compreendendo um ingrediente ativo instável a ácido, em particular um inibidor de bomba de próton instável a ácido. A invenção também refere-se a processos para produzir a suspensão. A suspensão é particularmente adequada para administração de ingredientes ativos instáveis a ácido a pessoas que têm dificuldade de deglutir formas de dosagem sólidas como comprimidos ou cápsulas.
BR0115989-5A 2000-12-07 2001-12-05 Preparação farmacêutica na forma de uma suspensão compreendendo um ingrediente ativo instável a ácido BR0115989A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00126829 2000-12-07
PCT/EP2001/014254 WO2002045692A1 (en) 2000-12-07 2001-12-05 Pharmaceutical preparation in the form of a suspension comprising an acid-labile active ingredient

Publications (1)

Publication Number Publication Date
BR0115989A true BR0115989A (pt) 2004-01-13

Family

ID=8170596

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0115989-5A BR0115989A (pt) 2000-12-07 2001-12-05 Preparação farmacêutica na forma de uma suspensão compreendendo um ingrediente ativo instável a ácido

Country Status (10)

Country Link
US (1) US7357943B2 (pt)
EP (1) EP1341523B1 (pt)
JP (1) JP5009482B2 (pt)
KR (1) KR20030059318A (pt)
CN (1) CN100528232C (pt)
AU (1) AU2002234545A1 (pt)
BR (1) BR0115989A (pt)
CA (1) CA2430824C (pt)
ES (1) ES2403238T3 (pt)
WO (1) WO2002045692A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
MXPA05000301A (es) * 2002-07-03 2005-03-31 Abbott Lab Formas de dosificacion liquida de inhibidores de bomba de proton.
US20040005362A1 (en) * 2002-07-03 2004-01-08 Rajneesh Taneja Liquid dosage forms of acid labile drugs
WO2004063152A2 (en) * 2003-01-10 2004-07-29 Transform Pharmaceuticals, Inc. Lansoprazole formulations and related processes and methods
HRP20050399B1 (hr) 2003-03-10 2013-09-30 Takeda Gmbh Novi postupci za dobivanje roflumilasta
PE20050150A1 (es) * 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
CL2004000983A1 (es) * 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
CA2531566C (en) * 2003-07-18 2013-05-07 Santarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
US8663694B2 (en) * 2005-03-16 2014-03-04 Takeda Gmbh Taste masked dosage form containing roflumilast
CN101252914B (zh) * 2005-05-05 2013-03-27 塞诺菲-安万特美国有限责任公司 稳定的纳米粒制剂
US20070026071A1 (en) * 2005-07-28 2007-02-01 Qpharma, Llc Magnesium salt proton pump inhibitor dosage forms
EP1747776A1 (en) * 2005-07-29 2007-01-31 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising granular pantoprazole
US20100029241A1 (en) * 2008-08-01 2010-02-04 Justin Russell Morga Rf filter/resonator with protruding tabs
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US9833408B1 (en) * 2016-07-28 2017-12-05 Allen Greenspoon Orally administrable formulation
US20200179411A1 (en) * 2017-08-25 2020-06-11 L. Perrigo Company Pharmaceutical suspensions for bismuth subsalicylates

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
FI90544C (fi) 1986-11-13 1994-02-25 Eisai Co Ltd Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi
US4999189A (en) * 1988-11-14 1991-03-12 Schering Corporation Sustained release oral suspensions
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
SE9301489D0 (sv) * 1993-04-30 1993-04-30 Ab Astra Veterinary composition
US5708017A (en) * 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
SI1037607T1 (en) * 1997-12-08 2004-08-31 Altana Pharma Ag Novel suppository form comprising an acid-labile active compound
BR0008403A (pt) 1999-02-23 2002-01-29 Merck & Co Inc Formulação farmacêutica para administração oral
EP1616562A1 (en) * 1999-06-07 2006-01-18 ALTANA Pharma AG Novel preparation and administration form comprising an acid-labile active compound
DE19925710C2 (de) 1999-06-07 2002-10-10 Byk Gulden Lomberg Chem Fab Neue Zubereitung und Darreichungsform enthaltend einen säurelabilen Protonenpumpenhemmer
ES2375269T3 (es) * 2000-12-07 2012-02-28 Nycomed Gmbh Preparado farmacéutico en forma de una pasta que comprende un ingrediente activo l�?bil ante los �?cidos.
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
EP1341528B1 (en) * 2000-12-07 2012-01-18 Nycomed GmbH Rapidly disintegrating tablet comprising an acid-labile active ingredient

Also Published As

Publication number Publication date
WO2002045692A1 (en) 2002-06-13
ES2403238T3 (es) 2013-05-16
US7357943B2 (en) 2008-04-15
CA2430824A1 (en) 2002-06-13
CN100528232C (zh) 2009-08-19
CA2430824C (en) 2012-05-08
KR20030059318A (ko) 2003-07-07
EP1341523B1 (en) 2013-01-23
JP5009482B2 (ja) 2012-08-22
US20040052832A1 (en) 2004-03-18
EP1341523A1 (en) 2003-09-10
CN1541091A (zh) 2004-10-27
JP2004514735A (ja) 2004-05-20
AU2002234545A1 (en) 2002-06-18

Similar Documents

Publication Publication Date Title
BR0115989A (pt) Preparação farmacêutica na forma de uma suspensão compreendendo um ingrediente ativo instável a ácido
CY1112510T1 (el) Φαρμακευτικο παρασκευασμα υπο τη μορφη παστας το οποιο περιεχει ενα ασταθες στα οξεα δραστικο συστατικο
RU2479316C2 (ru) Пероральные композиции, продукты и способы применения
JP2025109935A (ja) カンナビジオールを含む局所製剤、組成物の調整方法およびその方法
TW200630123A (en) Oral medicinal product with modified release of at least one active principle in multimicrocapsular form
US20090191288A1 (en) Composition to Treat Herpes, Pseudomonas, Staph, Hepatitis and Other Infectious Diseases
BR0003158A (pt) Formulação de dosagem oral de derretimentoinstantâneo
AR017984A1 (es) Proceso para formar una composicion farmaceutica de topiramato y composicion farmaceutica de topiramato
CZ359498A3 (cs) Kompozice a její použití k přípravě farmaceutického prostředku pro léčení infekčních onemocnění a farmaceutický přípravek tuto kompozici obsahující
BR0313424A (pt) Forma de dosagem e processo para a preparação de uma forma de dosagem
US9662360B2 (en) Treatment of herpes, pseudomonas, staph, and hepatitis
BR0107899A (pt) Processo para produzir uma preparação de ingrediente ativo compreendendo ibuprofeno, preparação de ingrediente ativo, uso da mesma, preparação farmacêutica, uso da mesma, processo para produzir formas de dosagem sólidas, e, forma de dosagem sólida
IS7006A (is) Tvívetnis 3-piperidínóprópíófenon og lyf sem innihalda téð efnasambönd
ECSP034826A (es) Método para fabricar una composición farmacéutica de dosis baja
KR970032872A (ko) 아세틸살리실산을 함유하는 피부 손상 처치용 약물
BR0116653A (pt) Medicamento contendo uma poliamina como substância ativa
BR0207866A (pt) Uso de flumazenil na preparação de um medicamento para o tratamento da dependência de cocaìna
TW200602090A (en) Antibiotic-based pharmaceutical formulation in microcapsular form
AU2008253776A8 (en) Agent, pharmaceutical composition, and method for treating the ethyl alcohol and/or narcotic dependence
RU2008110933A (ru) Применение амброксола для лечения риновирусных инфекций
CA2429793A1 (en) Interferon therapeutic effect enhancer
WO2004033484A3 (en) Use of stable glutamine derivatives to improve drug absorption
RU2120284C1 (ru) Комбинированное противовоспалительное, анальгезирующее, жаропонижающее средство
PT1150660E (pt) Formulacao farmaceutica efervescente contendo metamizole
EA200501621A1 (ru) Антигриппозное средство

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: NYCOMED GMBH (DE)

Free format text: ALTERADO DE: ALTANA PHARMA AG

B25A Requested transfer of rights approved

Owner name: DR. RANGO DIETRICH (DE)

Free format text: TRANSFERIDO DE: NYCOMED GMBH

B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.